Clinical Trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LG-0317 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is the first administration of LG-0317 to humans. The purpose of the study is to evaluate safety/tolerability and pharmacokinetics in healthy subjects. The intention of this study is to provide confidence in the safety of the molecule to inform progression to further proof-of-concept studies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-21
Trial Details
NCT Number NCT07522970
Lead Sponsor LinGang Laboratory
Conditions Healthy Volunteers
Enrollment 100 participants
Start Date 2026-04-20
Primary Completion 2026-09-10 (estimated)
Study Completion 2026-09-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-25